We recently published 10 Stocks With Massive Gains; 5 at Record Highs. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was one ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...

Eli Lilly is a safer way to capitalize on AI-driven drug discovery.

Humanoid robots are a dead end; the real breakthrough is a self-improving SuperNet that manufactures itself — and everything ...

Here is the AI research roadmap for 2026: how agents that learn, self-correct, and simulate the real world will redefine ...

I played these 25 cards the most and built so many decks around them — or at least dreamed how they might function in the ...

Broadcom enters 2026 at an inflection point, with strong tailwinds from its ASIC and Networking segments. Read why AVGO stock ...

The surge of AI has, for an array of users, complicated tasks such as fixing a blocked bank account, reporting fraud or ...

AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Insilico now has a pipeline of more than 40 AI-developed drugs it is developing for conditions such as cancer, bowel and kidney disease.

The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...

Takeda regains a majority of XOMA Royalty’s royalty interest in mezagitamab (TAK-079) –– XOMA Royalty will be entitled to payments based on a ...